Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Florida
Eli Lilly and Company
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute